Moderna's Norovirus Vaccine Early Trial Misses Endpoints, Stock Drops Over 7% Premarket
Taylor Wilson
Moderna's Phase 3 norovirus mRNA vaccine trial failed to meet its early-success statistical threshold, sending shares down more than 7% pre-market — a direct blow to the company's push to diversify beyond COVID.
What went wrong with the norovirus trial?
Moderna's Phase 3 trial for its norovirus mRNA vaccine failed to meet the pre-set statistical bar for declaring early success.
In plain terms = the trial isn't dead, but the data so far aren't strong enough to claim the vaccine works ahead of schedule. Moderna says it will enroll a new cohort and keep going.
This means → more patients, more time, and more uncertainty before any regulatory filing can begin.
Earnings actually beat — so why did the stock drop?
Q2 revenue came in at $145 million, up 2% year-over-year and well above the $103 million analysts expected. The per-share loss of $1.97 was narrower than last year's $2.13 and beat the Street's $2.01 estimate.
But the market cares more about pipeline progress right now. The norovirus setback undercut the narrative that Moderna is more than a COVID vaccine company.
This reflects a valuation regime shift: the stock no longer trades on quarterly beats — it trades on whether diversification can deliver.
What held revenue up this quarter?
The bright spot was UK COVID vaccine sales. Moderna has a long-term supply deal with the UK government, and UK deliveries offset declining sales in the US and South America.
The company reaffirmed full-year guidance of up to 10% revenue growth. It expects revenue split evenly between the first and second halves, with Q3 contributing roughly 55% of the back half.
This means → Moderna's financials still depend heavily on Spikevax (its COVID shot). Single-product risk has not meaningfully decreased.
Flu vaccine approval — the most important near-term catalyst?
The FDA must rule on Moderna's mRNA flu vaccine by August 5. In June, the FDA's advisory committee voted unanimously to recommend approval.
In plain terms = the advisory vote is a recommendation, not a binding order — but the FDA almost always follows it.
Notably, the FDA rejected Moderna's flu vaccine application in February, then quickly reversed itself — this signals that mRNA technology faces politicized regulatory pressure, and the outcome is not a purely scientific call.
Cancer therapy — the real long-term anchor?
Moderna's stock had nearly doubled from the start of the year through last Thursday. The core driver: its personalized cancer therapy — an mRNA vaccine custom-built to match each patient's tumor mutations — developed jointly with Merck.
The therapy has shown positive signals in preventing high-risk melanoma recurrence and is advancing across multiple other cancer types. Final-stage melanoma trial results could come this year.
This means → the norovirus setback is a short-term headwind. The two milestones that will determine whether the current valuation holds are the August 5 flu vaccine decision and when the melanoma data land.
Content is for reference only, not financial advice.